Limits...
Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.

Cheon YH, Kim MJ, Kang MG, Kim HJ, Lee SS, Kim CY, Jeon DH, Kim YE, Lee GW - Yonsei Med. J. (2011)

Bottom Line: There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer.The exact mechanism of bowel perforation in patients who received erlotinib remains unclear.In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy.

View Article: PubMed Central - PubMed

Affiliation: Division of Oncology-Hematology, Department of Internal Medicine, School of Medicine, Gyeongsang National University, 79 Gangnam-ro, Jinju 660-702, Korea. brightree@lycos.co.kr

ABSTRACT
Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum- based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer. The exact mechanism of bowel perforation in patients who received erlotinib remains unclear. In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy.

Show MeSH

Related in: MedlinePlus

(A and B) Submucosal edema and serosal hemorrhage of the perforated sigmoid colon.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3104451&req=5

Figure 3: (A and B) Submucosal edema and serosal hemorrhage of the perforated sigmoid colon.

Mentions: After resolution of pneumonia via empirical antibiotic treatment for 14 days, a scheduled sigmoid colon resection and primary anastomosis were performed at the Department of General Surgery. Surgical pathologic findings included submucosal edema and serosal hemorrhage of the perforated sigmoid colon, consistent with enterocutaneous fistula and no metastatic tumor foci in the sigmoid colon (Fig. 3A and B). Ten days postoperatively, the patient was discharged with complete recovery from the enterocutaneous fistula. She was alive and well on regular follow-up at the outpatient clinic, with no evidence of lung cancer progression.


Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.

Cheon YH, Kim MJ, Kang MG, Kim HJ, Lee SS, Kim CY, Jeon DH, Kim YE, Lee GW - Yonsei Med. J. (2011)

(A and B) Submucosal edema and serosal hemorrhage of the perforated sigmoid colon.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3104451&req=5

Figure 3: (A and B) Submucosal edema and serosal hemorrhage of the perforated sigmoid colon.
Mentions: After resolution of pneumonia via empirical antibiotic treatment for 14 days, a scheduled sigmoid colon resection and primary anastomosis were performed at the Department of General Surgery. Surgical pathologic findings included submucosal edema and serosal hemorrhage of the perforated sigmoid colon, consistent with enterocutaneous fistula and no metastatic tumor foci in the sigmoid colon (Fig. 3A and B). Ten days postoperatively, the patient was discharged with complete recovery from the enterocutaneous fistula. She was alive and well on regular follow-up at the outpatient clinic, with no evidence of lung cancer progression.

Bottom Line: There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer.The exact mechanism of bowel perforation in patients who received erlotinib remains unclear.In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy.

View Article: PubMed Central - PubMed

Affiliation: Division of Oncology-Hematology, Department of Internal Medicine, School of Medicine, Gyeongsang National University, 79 Gangnam-ro, Jinju 660-702, Korea. brightree@lycos.co.kr

ABSTRACT
Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum- based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer. The exact mechanism of bowel perforation in patients who received erlotinib remains unclear. In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy.

Show MeSH
Related in: MedlinePlus